Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Health Canada/RISPERIDONE

Authorized

STANDARD

RISPERIDONE

sivem pharmaceuticals ulc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 590bd10056ea1417
Company: sivem pharmaceuticals ulc
Type: Standard

Approval Details

Approval Id: 590bd10056ea1417
Drug Approval Canada Name: RISPERIDONE
Product Name: RISPERIDONE
Status: Marketed
Status Date: 2023-11-09
Original Market Date: 2023-11-09
Din: 02533804
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 28:16.08.04
Atc Original: N05AX08 RISPERIDONE
Atc Name: n 05 ax 08
Aig Number: 0124332006
Company Name: sivem pharmaceuticals ulc
Company Address: 4705 Dobrin Street, Saint-Laurent, Quebec, Canada, H4R 2P7

Active Ingredients

RISPERIDONE

0.25 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

590bd10056ea1417

Type

Standard

Back to Health Canada Approvals

RISPERIDONE - Health Canada Drug Approval Details